A single center, open label pilot study to evaluate RNS60 as a treatment for amyotrophic lateral sclerosis (ALS) at Massachusetts General Hospital (MGH) started treatment of its first patient on October 30.

The purpose of the study, which was initiated by the study investigators, is to determine whether RNS60 is safe and tolerable in ALS patients, and whether it modulates blood and brain biomarkers of inflammation in ALS.

More information can be found at: https://clinicaltrials.partners.org/study/9709 & https://www.clinicaltrials.gov/